1 / 14

Single immediate postoperative instillation of chemotherapy in patients with Ta/T1 bladder TCC

Single immediate postoperative instillation of chemotherapy in patients with Ta/T1 bladder TCC. Dr Charles Chabert. Background. 70-80% present with superficial disease BCG treatment of choice if high risk 50% recurrence but < 5% progression. Sylvester et al J Urol 171, June 2004. Background.

ronald
Télécharger la présentation

Single immediate postoperative instillation of chemotherapy in patients with Ta/T1 bladder TCC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Single immediate postoperative instillation of chemotherapy in patients with Ta/T1 bladder TCC Dr Charles Chabert

  2. Background 70-80% present with superficial disease BCG treatment of choice if high risk 50% recurrence but < 5% progression Sylvester et al J Urol 171, June 2004

  3. Background EAU guidelines recommend single dose ? Value in low risk & multiple tumours Sylvester et al J Urol 171, June 2004

  4. Materials & methods Randomised trials with primary or recurrent Ta/T1 Exclusion of CIS Sylvester et al J Urol 171, June 2004

  5. Materials & Methods Primary end point: % of patients with a recurrence in the 2 treatment arms Decrease in Odds of recurrence calculated without time to recurrence Sylvester et al J Urol 171, June 2004

  6. Results 12 trials considered 5 exclusions; 4 inadequate randomisation 1 included CIS 7 trials entered into Meta-analysis Sylvester et al J Urol 171, June 2004

  7. Trial Characteristics Accural between 1981-1994 Median F/U: 3.4 years (2-10.7 yrs) 3 trials included only primary patients 2 trials only single tumours Sylvester et al J Urol 171, June 2004

  8. Trial Characteristics 4 different drugs used Epirubicin 3 trials Mitomycin C 2 trials Thiotepa 1 trial Pirarubicin 1 trial Sylvester et al J Urol 171, June 2004

  9. Patient Characteristics 1517 eligible patients from 7 trials 1476 had F/U 748 (50.7%) TUR only & 728 (49.3%) TUR + instillation Sylvester et al J Urol 171, June 2004

  10. Tumour Characteristics Predominantly low risk 89.2% primary tumours 84.3% single tumours 67.9% Ta 9.5% G3 Sylvester et al J Urol 171, June 2004

  11. Recurrence 629 (42.6%) of 1476 patients 362 (48.4%) TUR & 267 (36.7%) TUR + Chemo Decrease of 39% in odds of recurrence Sylvester et al J Urol 171, June 2004

  12. Recurrence Treatment effect similar for all agents No benefit with Thiotepa 849 single tumours: (41.5%) 47.5% TUR & 35.8% TUR + Chemo 111 multiple tumours: (74.8%) 81.5% TUR & 65.2% TUR + chemo Sylvester et al J Urol 171, June 2004

  13. Toxicity Mild irritative bladder symptoms in 10% Systemic toxicity extremely rare Allergic skin reactions 1-3% Sylvester et al J Urol 171, June 2004

  14. Summary NNT to prevent 1 recurrence: 8.5 One instillation cost effective Significantly reduces recurrence with minimal morbidity Sylvester et al J Urol 171, June 2004

More Related